218 related articles for article (PubMed ID: 18464113)
1. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.
Cil T; Altintas A; Pasa S; Bayan K; Ozekinci T; Isikdogan A
Leuk Lymphoma; 2008 May; 49(5):939-47. PubMed ID: 18464113
[TBL] [Abstract][Full Text] [Related]
2. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.
Yeo W; Chan PK; Ho WM; Zee B; Lam KC; Lei KI; Chan AT; Mok TS; Lee JJ; Leung TW; Zhong S; Johnson PJ
J Clin Oncol; 2004 Mar; 22(5):927-34. PubMed ID: 14990649
[TBL] [Abstract][Full Text] [Related]
3. A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?
Long M; Jia W; Li S; Jin L; Wu J; Rao N; Feng H; Chen K; Deng H; Liu F; Su F; Song E
Breast Cancer Res Treat; 2011 Jun; 127(3):705-12. PubMed ID: 21445574
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus reactivation in hepatitis B surface antigen seropositive patients with metastatic non-small cell lung cancer receiving cytotoxic chemotherapy: the efficacy of preemptive lamivudine and identification of risk factors.
Lin GN; Peng JW; Xiao JJ; Liu DY; Xia ZJ
Med Oncol; 2014 Aug; 31(8):119. PubMed ID: 25023055
[TBL] [Abstract][Full Text] [Related]
5. The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy.
Chen XQ; Peng JW; Lin GN; Li M; Xia ZJ
Med Oncol; 2012 Jun; 29(2):1237-41. PubMed ID: 21556931
[TBL] [Abstract][Full Text] [Related]
6. Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with Lamivudine.
Simpson ND; Simpson PW; Ahmed AM; Nguyen MH; Garcia G; Keeffe EB; Ahmed A
J Clin Gastroenterol; 2003 Jul; 37(1):68-71. PubMed ID: 12811213
[TBL] [Abstract][Full Text] [Related]
7. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy.
Yeo W; Steinberg JL; Tam JS; Chan PK; Leung NW; Lam KC; Mok TS; Johnson PJ
J Med Virol; 1999 Nov; 59(3):263-9. PubMed ID: 10502254
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
Papadopoulos N; Deutsch M; Manolakopoulos S; Bitsi C; Michalakeas H; Poulakidas H; Tsironi E; Giannouli S; Papatheodoridis GV; Koskinas J; Pectasides D
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175
[TBL] [Abstract][Full Text] [Related]
9. Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine.
Yeo W; Hui EP; Chan AT; Ho WM; Lam KC; Chan PK; Mok TS; Lee JJ; Mo FK; Johnson PJ
Am J Clin Oncol; 2005 Aug; 28(4):379-84. PubMed ID: 16062080
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of lamivudine prophylaxis against hepatitis B reactivation in breast cancer patients undergoing chemotherapy: a meta-analysis.
Liu JY; Sheng YJ; Ding XC; Tang H; Tong SW; Zhang DZ; Zhou Z; Hu P; Liao Y; Ren H; Hu HD
J Formos Med Assoc; 2015 Feb; 114(2):164-73. PubMed ID: 25678179
[TBL] [Abstract][Full Text] [Related]
11. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors.
Yeo W; Chan PK; Zhong S; Ho WM; Steinberg JL; Tam JS; Hui P; Leung NW; Zee B; Johnson PJ
J Med Virol; 2000 Nov; 62(3):299-307. PubMed ID: 11055239
[TBL] [Abstract][Full Text] [Related]
12. An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy: a pilot study.
Wu XY; Li X; Chen ZH; Wen JY; Lin Q; Xing YF; Dong M; Wei L; Wang TT; Chen J; Lin ZX; Wan XB; Ruan DY; Ma XK
Tumour Biol; 2013 Apr; 34(2):909-18. PubMed ID: 23269606
[TBL] [Abstract][Full Text] [Related]
13. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.
Yeo W; Ho WM; Hui P; Chan PK; Lam KC; Lee JJ; Johnson PJ
Breast Cancer Res Treat; 2004 Dec; 88(3):209-15. PubMed ID: 15609123
[TBL] [Abstract][Full Text] [Related]
14. Lamivudine for the prevention of hepatitis B virus reactivation after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with advanced or relapsed non-Hodgkin's lymphoma single institution experience.
Huang H; Cai Q; Lin T; Lin X; Liu Y; Gao Y; Peng R
Expert Opin Pharmacother; 2009 Oct; 10(15):2399-406. PubMed ID: 19761353
[TBL] [Abstract][Full Text] [Related]
15. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
[TBL] [Abstract][Full Text] [Related]
16. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.
Rossi G; Pelizzari A; Motta M; Puoti M
Br J Haematol; 2001 Oct; 115(1):58-62. PubMed ID: 11722410
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of the prophylactic effect of nucleosides against reactivation of HBV in HBsAg-positive patients with non-hepatic tumors after chemotherapy].
Zhang HY; Liu ZG; Zhang Z; Gong HY
Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):459-62. PubMed ID: 20819491
[TBL] [Abstract][Full Text] [Related]
18. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers.
Shibolet O; Ilan Y; Gillis S; Hubert A; Shouval D; Safadi R
Blood; 2002 Jul; 100(2):391-6. PubMed ID: 12091327
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy.
Hui CK; Cheung WW; Au WY; Lie AK; Zhang HY; Yueng YH; Wong BC; Leung N; Kwong YL; Liang R; Lau GK
Gut; 2005 Nov; 54(11):1597-603. PubMed ID: 16000641
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
